SEC Form 4 · accession 0001209191-18-029518
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pedro Huertas
Officer — Chief Medical Officer
Period of report
May 10, 2018
Accepted (ET)
May 11, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2018 | A | 104,725 | $0.00 | A | 104,725 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $14.88 | May 10, 2018 | A | 104,725 | A | — | May 10, 2028 | Common Stock | 104,725 | 104,725 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award that will vest one quarter (1/4) of the RSUs on March 12, 2019 (the "Initial RSU Vesting Date") and one sixteenth (1/16) of the RSUs shall vest on each successive quarterly anniversary of the Initial RSU Vesting Date.
- F2This option will become exercisable with respect to one quarter (1/4) of the shares underlying the option shall vest on March 12, 2019 (the "Initial Option Vesting Date")and one sixteenth (1/16) of the shares underlying the option shall vest on each successive quarterly anniversary of the Initial Option Vesting Date.